leisure time -WSS

leisure time

author：focus 2025-09-27 19:38:25 - browse：9745

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Telehealth startups turn to complex chronic diseases

WSS

Readout LOUD podcast: What to know about H5N1 bird flu

Generative AI mines health records to identify patients’ social needs

The nurse manager staffing crisis is hurting patients

Brain worms: The science behind RFK Jr.'s parasitic infection

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

The SUPPORT Act is critical to fighting the opioid crisis

focus

leisure time

focus

23andMe had bad news about my health. I wish a person had delivered it

Medicare says breakthrough device reimbursement rule to come by summer

Drug repurposing or repositioning? The language matters

Designating disabled people as health disparity population is crucial

DIEP, the 'gold standard' of breast reconstruction, is under threat

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Hollywood unions extend contract negotiations for actors

DeSantis can now import cheaper drugs. But will Biden get credit?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Doulas covered by Medicaid under New York's new plan

hotspot

What nurses really want: sufficient staffing for patient care

As JPM 2024 winds down, some health tech firms project optimism

Designating disabled people as health disparity population is crucial

CDC wastewater surveillance dashboard to track bird flu hotspots

How I ended up pumping milk in a bathroom stall at JPM 2024

Shionogi licenses Pompe disease therapy from Maze Therapeutics

entertainment

Wikipedia

entertainment

hotspot